

---

## Xbrane Biopharma Q1 2025 - Transformative times

Redeye updates its view on Xbrane following a stronger-than-expected Q1 report, with both revenue and EBIT exceeding estimates. In the wake of the Alvotech deal, we see a new investment case emerging—still overshadowed by the turbulence of the past year, the current market cap remains modest for a commercial-stage biotech company.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Xbrane Biopharma Q1 2025 - Transformative times**